

Index

A

- Abnormal fetal, 444
- Abnormal karyotype, 492
- Abruption, 508–509
- Acid-base status, 458
- ACOG, 439, 450, 491
- Activated partial thromboplastin time (aPTT), 333
- Acute chest syndrome, 48, 479
- Acute maternal infection, 441
- Acute viral hepatitis, 335
- Allergen immunotherapy, 370
- Allergy, 360–361
- Alloimmunization, 457, 462–463, 528
 - amniocentesis, 35, 37
 - antepartum fetomaternal hemorrhage, 34
 - anti-D immune globulin, 34
 - fetal blood group, 33
 - Fisher-Race
 - nomenclature, 33
 - gestational age, complicated pregnancies, 36–37
 - intrauterine transfusion, 33
 - maternal levels, 33
 - middle cerebral artery
 - Doppler testing, 36
 - during pregnancy, 33–37
 - Rh D prevention, 3–8
 - Rh-negative woman,
 - screening, 34
- Alpha-globin gene, 480
- Alpha-thalassemia, 49, 482
 - carriers, 480–481
- Amniocentesis, 241, 330, 395, 414–415, 441, 453, 455, 463
 - with chromosomal microarray, 242
 - fetal aneuploidy, 251
 - with karyotype analysis with or without FISH, 242
 - membrane rupture after, 241
 - stillbirth, 90
- Amniotic fluid, 498–499
 - assessment and nonstress test, 328
 - measurement, 384
 - volume, 400
- Amniotic fluid index (AFI), 309, 361
- Amniotic sac, 394
- Ampicillin, 379
- Anaerobic metabolism, 524
- Anal canal, pressure of, 474
- Anal sphincter laceration, 219
- Anaphylaxis, 130, 529
- Anemia, 3, 317, 347, 478, 495
 - abnormal fetal
 - oxygenation, 86
 - autoimmune hemolysis, 83, 87
 - causes, 83, 87
 - chronic disease, 83, 87
 - Crohn's disease, 85–86

- Anemia (*cont.*)
- diagnosis, 84–86
 - early iron deficiency, 83, 87
 - hemoglobin and hematocrit levels, 84
 - hemoglobinopathies
 - screening, 83
 - iron supplementation, 87
 - macrocytic, 83
 - management, 86
 - maternal blood
 - transfusion, 86
 - microcytic, 84
 - parental iron, 87
 - prevalence of, 85
 - screening, 86, 87
 - serum ferritin levels, 84–85
 - structural
 - abnormalities, 85, 87
 - supplemental sustained-release iron
 - preparations, 85
 - treatment, 83
 - vitamin deficiencies, 83
- Anencephaly, 21
- Anesthesia, 363, 379
- Aneuploidy, 404
- low risk for, 426
 - risk of, 375, 416
 - screening for, 338, 406–407, 434–435
- Anit-B2 glycoprotein I, 459
- Antenatal corticosteroids, 286
- Antenatal surveillance, 450
- Antepartum fetal surveillance, 322, 329
- amniotic fluid measurement, 184
 - biophysical profiles, 179, 181, 183, 184
 - contraction stress tests, 179, 180
 - diabetic ketoacidosis, 183
 - fetal death prevention, 179
 - fetal kick count, 180
 - fetal testing performance, 183
 - indications, 182
 - intrauterine growth
 - restriction, 180, 184
 - nonstress tests, 179, 181
 - oligohydramnios, 179, 184
 - perinatal morbidity and mortality, 179
 - umbilical artery Doppler velocimetry, 182
- Antibiotic administration, 443
- Antibiotic prophylaxis, 336, 380, 449, 522
- BMI, 130
- labor and delivery
 - administration, 131
 - cefazolin, 131
 - E. coli* sepsis and resistance, 129
 - for endocarditis, 132
 - intraoperative dose, 131–132
 - lower serum levels, 130
 - manual placenta
 - extraction, 133
 - patient screening, 132
 - resistant flora, 129
 - risk factors, 130
 - transverse cesarean
 - section, 131
- Antibiotics, 379, 529
- Anticardiolipin antibodies, 459
- Anticoagulation, 316, 397, 439, 502–503
- Antidepressants, atypical, 469
- Anti-D immune globulin, 3, 319, 441, 442, 451, 452, 463, 517, 522
- abdominal trauma, 6
 - antenatal surveillance, 5
 - bleeding, indirect Coombs
 - test, 6, 8
 - CVS, 5
 - intrauterine pregnancy, 7, 8
 - postpartum administration, 4
 - prophylaxis, 505, 515
 - standard prophylactic
 - dose, 4, 8

- Antiphospholipid antibody syndrome (APS), 405, 406, 482, 494–495
- anit-B2 glycoprotein I, 148
- antenatal testing, 150
- anticardiolipin antibodies, 148
- aspirin, 149, 150
- clinical criteria, 149
- clinical surveillance, 149, 150
- diagnostic criteria, 147
- DVT with, 150
- lab criteria, 147–148
- lupus anticoagulant, 148
- pregnancy-induced hypertension, 148
- pregnancy loss scenarios, 148–149
- prophylactic anticoagulation, 149, 150
- severe preterm preeclampsia, 148
- thrombosis risk, 149
- venous and arterial thromboses, 147
- Antipsychotics, 467
- Antithrombin III deficiency, 502
- Anxiety disorder, 420
- APS. *See* Antiphospholipid antibody syndrome (APS)
- aPTT. *See* Activated partial thromboplastin time (aPTT)
- Asperger's syndrome, 79
- Asthma, 348, 351–352, 455, 456, 506, 507
- adrenal crisis, 73
- airway obstruction, 67
- allergen immunotherapy, 71
- beta-2 agonists therapy, 71, 73
- breastfeeding
- contraindications, 73
- bronchospasm risk, 72
- chronic airway inflammation, 67
- diagnosis, 70
- dyspnea, 70–71
- fetal surveillance, 72
- inhaled corticosteroid, 72
- medications, 67–68, 72, 475, 476
- nighttime awakening, 69
- normal activity limitation, 70
- patient counselling, 71
- patient education, 67
- peak expiratory flow rate, 71–72
- prevention, 67
- pulmonary function parameters, 68–69
- severity classification, 69–70
- symptoms, 69, 70
- treatment, 67
- Asthmatics, 41, 476
- B**
- Bacterial infections, 129
- Bariatric surgery, 325, 382, 386, 387, 392
- acute abdominal pain, 97
 - cesarean rates, 98
 - gestational diabetes, 97
 - laboratory testing, 97
 - malabsorptive procedures, 98
 - micronutrients, 97
 - nutritional deficiencies, 95
 - nutrition and vitamin intake, 98
 - patient counselling, 97
 - preeclampsia, 97
 - treatment, 96
- Baseline tachycardia, 103, 385
- Beta-adrenergic receptor agonists, 288, 448
- Betamethasone, 383
- Beta-thalassemia, 48, 49, 481
- Biophysical profiles, 179, 181, 183, 184, 400, 429
- Biparietal diameter, 413

- Bipolar disorder, 444, 470
 - antidepressants, 76, 81
 - electroconvulsive therapy, 76, 81
 - lamotrigine, 76, 80, 81
 - lithium control, 79, 81
 - occurrence, 78, 81
 - postnatal death, 76, 81
 - psychotherapy, 76, 81
- Bishop score, 109, 110, 112, 527
- Blood-borne infections, 425
- Blood glucose levels, 439
- Body mass index (BMI), 95, 225, 228, 373, 392, 397, 442, 518
- Brachial nerve palsy, 418
- Brachial plexus injury, 18, 314, 443, 525
- Bradycardia, 385
- Breastfeeding, 14, 15, 57, 64, 350, 429, 476
 - anticoagulants, 140
 - contraindications, 73
- Breech, 484

- C**
- Calcium channel blocker, 287, 447
- Carbamazepine, 371, 523
- Cardiomyopathy, 437
- Cardiopulmonary arrest, 525
- Cefazolin, 229, 344, 409
- Cell-free fetal DNA, 249, 251, 415, 417, 452, 530
- Cephalohematomas, 505
- Cerclage, 387, 426, 467
 - placement, 507
 - removal, 511
- Cerebral palsy, 316
- Cervical insufficiency, 386, 392, 471–472
 - cerclage
 - placement, 176
 - removal, 177
 - types, 174, 175
 - cervical length, 175, 176
 - diagnosis, 173
 - lacerations, 257, 358
 - length, 417–419, 508
 - painless cervical dilation, 173
 - preterm premature rupture, membranes, 177
 - remodeling, 110
 - risk factors, 173–174
 - transabdominal cerclage, 174
 - treatments, 174
 - ultrasound monitoring, 176
- Cervical ripening, 319, 486, 510
- Cervix, 365, 371
- Cesarean section, 131, 218, 359, 370, 374, 383, 517
 - rate of, 217, 324
- Chickenpox, 199, 202, 206
- Childhood obesity, 226
- Chorionic villus sampling (CVS), 5
- Chromosomal abnormalities, 237, 238, 309, 343, 361
- Chromosomal microarray analysis, 239, 341, 380
- Chromosomes, 444
- Chronic immune thrombocytopenia, 362
- Chronic liver disease, 337
- Clavicular fracture, 314
- Clindamycin, 379
- Clot observation test, 41, 475
- Clotting abnormalities, 41, 475
- Coagulopathies, 399
- Congenital anomalies, 317
- Congenital varicella syndrome, 199, 202, 205, 369
- Contraction stress test, 441
- Corticosteroids, 367
- Cranial neural tube defects, 524
- Critical care
 - pregnancy
 - cardiopulmonary arrest, 279
 - fetal heart tones, 280
 - ICU, 278–280

- laboratory values, 278
- sepsis, 280
- skills, 277
 - in United States, 277
- skills, 322
 - in United States, 321
- Crohn's disease (CD), 85–86
- Cryoprecipitation, 496
- Cystic hygroma, 456
- Cytokines, 526–527
- Cytomegalovirus (CMV), 317, 419
 - acute maternal infection, 203–204
 - amniocentesis, 204
 - childhood illness, 199
 - hearing loss, 199
 - in utero infection, 199
 - mononucleosis-like syndrome, 199
 - primary, 199
 - secondary infection, 200
 - sexual contact, 199
 - ultrasound surveillance, 204
 - vertical transmission, 200

D

- Daily dietary allowance, 518–519
- Dane particle, 328
- Deep vein thrombosis (DVT), 494–495, 506
 - diagnosis, 136–137
 - oral contraceptives, 137
 - prophylactic anticoagulation, 137
 - symptoms, 136
 - therapeutic anticoagulation, 138
- Delayed pushing, 368
- Delaying delivery, 348
- Delivery, 402
- Depression, pregnancy
 - antidepressants, 79
 - fetal growth restriction, 77
 - low birthweight, 77

- paroxetine, 78, 81
- premature birth, 77
- Developmental delay, 79
- Dextrose, 353
- Diabetes mellitus, 501
 - decreased insulin sensitivity, 27
 - pancreas, autoimmune destruction, 27
 - pregestational (*see* Pregestational diabetes mellitus) types, 27
- Diabetic ketoacidosis, 30, 315, 429, 450
- Diabetic nephropathy, 29, 450
- Diarrhea, 42, 476
- Dichorionic-diamniotic twin gestations, 345, 368, 391
- Dichorionicity, 315
- Discordance, 398
- Dizygotic twin, 460
- Doppler velocimetry, 432
- Down syndrome, 245, 246, 248, 249, 339, 434, 518
- Doxylamine, 332, 412
- Dumping syndrome, 98, 388
- Dystocia, 378

E

- Echogenic bowel, 375
- Edinburgh Postnatal Depression Scale, 75
- Electroconvulsive therapy, 499
- Electronic fetal monitoring (EFM), 315, 413, 417
 - baseline rate, tachycardia, 102
 - fetal heart rate tracing patterns, 101
 - with fetal heart tones, 104
- interobserver and intraobserver reliability, 101
- preterm deliveries and term deliveries, 104
- sensitivity of, cerebral palsy, 104

- Endoanal ultrasonography, 256, 417
- Enteral nutrition, 354
- Epidural analgesia, 10, 506, 518
 chronic back pain, 13
 effect of, labor, 13, 15
 maternal fever, 11
- Epidural anesthesia, 254, 508
- Epidural-related fever, 13, 440
- Epidural/spinal hematoma, 362
- Episiotomies, 254, 255, 369, 438, 469
- Estrogen, insulin sensitivity, 524
- External cephalic version (ECV), 328, 366, 372, 378, 394, 485
 anti-D immune globulin, 234–235
 breech, 231
 cesarean section, 232, 234, 378–379
 fetal heart rate decelerations, 232
 fetal heart tones, 234
 parous patient, 233
 regional anesthesia, 233
 terbutaline, 233
- F**
- Facial dysmorphism, 79
- Facial nerve palsy, 220, 417
- Factor V Leiden
 heterozygote, 169, 440
 homozygote, 169, 440
- Failed operative vaginal delivery, 327
- Fascial sheath, 359
- Fatty liver disease, 333
- FDA pregnancy, 425
- Fecal-oral transmission, 325
- Femoral diaphysis, 413
- Fetal anemia, 400, 457
- Fetal aneuploidy
 AFP, 247
 amniocentesis, 251
 cell-free fetal DNA, 249, 251
 choroid plexus cyst, 250
 counsel, 248, 249
 CVS, 251
 Down syndrome, 245, 246, 248, 249
 echogenic intracardiac focus, 248
 elevated unconjugated estriol, 251
 fetal ECHO, 249
 gestational age, 246
 mother's age-adjusted risk, 251
 neural tube defects, 246
 nuchal translucency, 251
 quad screen, 247
 screening for, 246
 second trimester, 247
 serum screening, 249
 T18 fetus, 250
 trimester screen, 247
 trisomy 18, 250
 ultrasonographer, 246
 ultrasound, 248–250
- Fetal anomalies, 518
- Fetal autopsy, 501
- Fetal cholestatic hepatitis, 81, 468
- Fetal fibronectin, 402
- Fetal gastroschisis, 225
- Fetal growth, 489
- Fetal growth restriction
 abnormal fetuses, 151
 chromosomal abnormalities, 152
 growth restriction patterns, 151
 IUGR, 154
 morbidity and mortality, 152
 pathology, 152
 perinatal mortality, 151
 placental insufficiency, 151
 prevention, 153
 recurrence risk, 153
 restriction, 411, 432
 small fetuses, 151

structural malformations, 152
 ultrasonography, 154
 umbilical artery Doppler
 velocimetry, 153
 Fetal heart rate, 451, 459, 488, 489
 anomaly, 421
 tracing, 384–385, 421, 515, 519
 category II, 461
 category III, 495
 Fetal heart tones, 315, 354, 389,
 420, 451, 526
 Fetal intracranial hemorrhage,
 465–466
 Fetal kick counting, 407
 stillbirth, 92
 Fetal macrosomia, 221, 226, 528
 Fetal middle cerebral artery, 380
 Fetal movement, 330
 Fetal-neonatal alloimmune
 thrombocytopenia, 313,
 314, 445
 Fetal neural tube defects, 319,
 373
 Fetal pulmonary hypoplasia, 461
 Fetal sleep cycle, 373
 Fetal spina bifida, 465
 Fetal surgery, 376
 Fetal surveillance, 498, 504
 Fetal tachycardia, 126, 515
 Fetal thyroid, 462
 Fetal thyrotoxicosis, 192, 462
 Fetal valproate syndrome, 79, 522
 Fetal weight, 331, 359
 Fetomaternal hemorrhage, 4, 8,
 435
 Fingernail hypoplasia, 79, 81
 FISH analysis, 238
 Fisher-Race nomenclature, 33,
 528
 Floppy infant syndrome, 77, 80, 475
 Folic acid, 367, 509
 Fondaparinux, 335
 Forceps
 operative vaginal delivery,
 218, 220, 222, 325
 vacuum extraction, 222

G

General analgesia, 9
 preeclampsia, 12
 uterine relaxants, 11, 15
 General anesthesia, 446
 Genetic disorders, prenatal
 diagnostic testing
 for, 425
 abnormal fetal, 237
 amniocentesis
 with chromosomal
 microarray, 242
 with karyotype analysis
 with or without
 FISH, 242
 membrane rupture
 after, 241
 balanced translocations and
 triploidies, 239
 blood-borne infections, 242
 chromosomal abnormality,
 237, 238
 chromosomal microarray
 analysis, 239
 CVS, 240, 241
 FISH analysis, 238
 karyotype
 analysis, 238, 239
 limb reduction defects, 240
 metaphase, mitosis, 238
 mitochondria, 238
 neonatal phenotype, 237
 pregnancy loss rate, 240
 preimplantation genetic
 diagnosis, 240
 risk of, 330
 structural chromosomal
 abnormalities, 241
 Genital HSV, 424
 Genital tract hematoma, 40–41,
 473
 Gestational ages, 313, 315, 340,
 368, 394, 395, 404, 408,
 410, 421, 424, 426, 429,
 430, 433, 456, 458, 468,
 472, 480, 527

- Gestational diabetes, 229, 324,
344, 355, 356, 361, 363,
382, 428, 429, 454, 458
antenatal surveillance, 161
caloric allotment, 159
definition, 158
delivery of, 162
diagnostic criteria, 158
glucose screening, 158, 159
glyburide and metformin, 160
hypertensive disorders, 157
incidence of, 157
insulin control, 162
insulin dosage, 160
insulin therapy, 157
management, 159
nutritional and dietary
counseling, 157
oral hypoglycemic therapy,
157
pharmacologic treatment, 160
polycystic ovarian syndrome,
161
screening, 157, 158
treatment, 157, 159
- Gestational thrombocytopenia,
326, 392, 393, 421
- Gestational weight gain, 227, 364
- Glyburide, 363, 502
- Graves' disease
methimazole, 192
umbilical cord sampling, 193
- H**
- Hadlock's formula, 359
- hCG, 211, 529–530
- Hemabate, 476
- Hematocrit levels, 406, 497
- Hemoglobin, 406, 437, 500
hemoglobin A, 47, 478–479
- Hemoglobinopathies, 47–51, 322,
481
CBC, 49, 51
hemoglobin electrophoresis,
49, 51
sickle cell disease (*see* Sickle
cell disease)
thalassemias, 48, 49
- Hemolytic disease, 3, 8, 319
- Hemorrhage, 493
- Heparin, 335, 427, 462
- Heparin-induced
thrombocytopenia, 138,
335
- Hepatitis, 333, 337
hepatitis A, 325, 348
immune globulin, 351
hepatitis B, 328, 337, 339, 342,
353
vaccine, 334
hepatitis C, 335, 337, 342, 345
hepatitis D, 333, 337
vertical transmission of, 344
- Hepatocellular carcinoma, 320
- Herpes simplex virus (HSV), 403,
422, 430, 432
antiviral agents, 56
breastfeeding, 57
cesarean delivery, 55
diagnosis, 53
infections, 405, 408
intrapartum infection, 57, 58
neonate, vertical transmission,
55
oropharyngeal disease, 57, 58
PCR techniques, 54
preterm premature rupture of
membranes, 57
screening, 56, 426
suppressive viral therapy, 56
viral detection, 54
- Hyperbilirubinemia, 81, 468
- Hyperemesis gravidarum, 342,
436, 469, 516
clinical diagnosis, 210
diagnosis, 214
electrolyte abnormalities, 210
ketonuria, 210
low birth weight, 212
weight loss, 210
- Hyperkalemia, 347

- Hypertensive disorders, 458
- Hyperthyroidism, 488
 - adverse effects, 192
 - fetal, 192
 - methimazole, 191
 - propylthiouracil, 191
 - severe preeclampsia, 192
- Hypogastric artery ligation, 43
- Hypoglycemia, 514–515
- Hypotension, 42, 476
- Hypothyroidism, 191, 410
- Hysterectomy, 497

- I**
- ICU, 322, 452, 514, 526
- IgG antibodies, 341
- IgG positive, 512
- Immune thrombocytopenia, 362
- Immune thrombocytopenia purpura (ITP), 392, 445
- Impaired fetal growth, 374
- Induction of labor (IOL), 117, 128, 190, 318, 319, 363, 402, 492
 - augmentation, 109
 - Bishop score, 109, 110, 112
 - cervical remodeling, 110
 - cervical ripening, 109, 112, 113
 - cesarean delivery, 109
 - contraction stimulation, 109
 - definition, 109
 - Foley catheter, 110
 - incidence, 109
 - indications, absolute and relative, 109
 - membrane stripping, 111
 - misoprostol, 110, 112–113
 - oxytocin infusion, 111
 - prostaglandin, 110–111
 - tachysystole, 111
 - uterine incision, intrauterine fetal demise, 114
 - uterine response to pitocin, 111
- Inhaled anesthetics, 519–520
- Inherited thrombophilias
 - antithrombin deficiency, 167
 - arterial and venous clots, 165
 - classification, 165
 - contraceptions, 170
 - decreased fibrinolysis, 165
 - factor V Leiden heterozygote, 166
 - fetal loss, 165
 - heparin, 170
 - insulin resistance and hyperlipidemia, 165
 - postpartum anticoagulation, 168
 - procedure-related bleeding, 170
 - prophylactic anticoagulation, 169
 - protein S deficiency, 166
 - prothrombin G20210A mutations, 166
 - risk factors, 165, 166
 - screening, 166–168
 - stillbirth, negative predictive value, 182
 - unfractionated heparin, 168
 - venous thrombosis, 166
- Insulin, 357, 358, 363, 503, 514
- Interphase, karyotype analysis, 524
- Intracranial hemorrhage, 396
- Intrapartum fetal heart rate monitoring
 - abnormal fetal acid-base status, 104
 - bradycardia, 103
 - decelerations, early and late, 102, 107
 - labor inducing agent, 107
 - magnesium sulfate, 105
 - maternal blood pressure monitoring, 107
 - maternal supplemental oxygen, 106
 - minimal baseline variability, 102, 103, 106

- Intrapartum fetal (*cont.*)
- moderate baseline variability
 - with accelerations and early decelerations, 103
 - recurrent late
 - decelerations, 103
 - without decelerations/accelerations, 104
 - normal acid-base status, 105
 - recurrent variable
 - decelerations, 103
 - regional anesthesia, 105
 - sinusoidal pattern, 103
 - tocolytic therapy, 106
 - tracings
 - amnioinfusion, 125
 - category I, 123, 125
 - category II, 125
 - category III, 127–128
 - intermittent variable decelerations, 125
 - labor and delivery, 124
 - moderate variability/accelerations, 125
 - neonatal outcomes, 128
 - pathophysiology, 123
 - preterm labor, 127
 - prolonged deceleration, 126–127
 - recurrent late
 - decelerations, 125
 - resuscitative measures, 128
 - uterine contraction, 124
 - transcervical amnioinfusion, 106
 - transient sinusoidal pattern, 105
 - umbilical cord prolapse, 107
 - Intrauterine fetal demise, 423
 - Intrauterine gestation, 391
 - Intrauterine growth, , 491, 496
 - Intrauterine growth restriction (IUGR), 356, 357, 400, 430, 457
 - intrauterine infection, 152
 - maternal disorders, 152
 - multiple gestation, 152
 - tobacco use during pregnancy, 152
 - twins, 345
 - Intrauterine infection, 152, 357
 - Intrauterine pregnancy, 320, 412, 435, 479
 - Intravenous immunoglobulins, 366
 - Iron-binding capacity, 438
 - Iron deficiency anemia, 84, 85, 318, 495, 495
- K**
- Karyotype analysis, 238, 239, 341, 501, 524
 - Kell alloimmunization, 34, 36, 37, 457, 529
- L**
- Labor and delivery, 9, 402
 - anesthesia administration, 499–500
 - blood glucose levels, 439
 - breastfeeding, 14, 15
 - chronic back pain, 13, 15
 - epidural analgesia during, 512
 - epidural placement, 13, 15, 440
 - management vs. induction, 492
 - pain control during, 521
 - parental and regional anesthesia, 10, 15
 - parental fentanyl, pain control, 13, 15
 - prophylactic antibiotics administration, 131
 - cefazolin, 131
 - E. coli* sepsis and resistance, 129
 - for endocarditis, 132
 - intraoperative dose, 131–132

- in labor and delivery
 - lower serum levels, 130
 - manual placenta
 - extraction, 133
 - patient screening, 132
 - resistant flora, 129
 - risk factors, 130
 - transverse cesarean
 - section, 131
 - Labor induction, 319, 363, 402
 - augmentation, 109
 - Bishop score, 109, 110, 112
 - cervical remodeling, 110
 - cervical ripening, 109, 112, 113
 - cesarean delivery, 109
 - contraction stimulation, 109
 - definition, 109
 - Foley catheter, 110
 - incidence, 109
 - indications, absolute and
 - relative, 109
 - membrane stripping, 111
 - misoprostol, 110, 112–113
 - oxytocin infusion, 111
 - prostaglandin, 110–111
 - tachysystole, 111
 - uterine incision, intrauterine
 - fetal demise, 114
 - uterine response to pitocin,
 - 111
 - Lamotrigine, 327, 340
 - Late-term pregnancies, 314
 - cesarean delivery, 188
 - due date estimation, 188, 190
 - intrauterine gestation, 187
 - management, 189
 - membrane sweeping, 188
 - morbidities, 187
 - oligohydramnios, 189
 - primary cesarean delivery,
 - 190
 - risks, 188
 - Latex, 360
 - LEEP procedure, 416
 - Live-born infants, 407
 - Local analgesia, 9
 - side effects, 12, 15
 - Local anesthetics, 498
 - Low birth weight infant
 - population, 522
 - Low-molecular-weight heparin,
 - 403, 404, 439
 - Lupus anticoagulant, 459
- M**
- Macrocytic anemia, 83, 485
 - Macrosomia, 227, 334, 407
 - brachial plexus injuries, 299,
 - 301, 302, 335
 - clavicular fracture, 299
 - concerning for, 300–301
 - counselling, 301
 - fetal weight, 302
 - fetus, 443, 479
 - gestational age, 303
 - insulin therapy for diabetics,
 - 302
 - live-born infants, 303
 - macrosomic fetus, 300, 302
 - measurement for, 303
 - neonatal mortality, 303
 - prediction of, 300, 443
 - risk factor, 300, 331
 - shoulder dystocia, 18, 299,
 - 300, 302
 - stillbirth, 303
 - ultrasound, 301, 303
 - Magnesium, 319, 349, 377
 - Magnesium sulfate, 448, 500
 - Malabsorptive procedures, 390
 - Malignancy, 375
 - Manual placenta extraction, 471
 - Maternal anemia, 345
 - Maternal hyperthyroidism, 399
 - Maternal morbidity, 226, 523
 - Maternal opioid consumption, 15
 - Maternal serum alpha-
 - fetoprotein (MSAFP),
 - 24, 318, 526, 526
 - Mean corpuscular volume
 - (MCV), 406

- Mediolateral episiotomy, 355, 469
 - Membranes, premature rupture,
 - 428, 511, 527
 - false-negative test, 293
 - fetal fibronectin, 293
 - fetal pulmonary hypoplasia, 293
 - induction of labor, 294
 - intrauterine infection, 292
 - pregnancies, 291
 - preterm PROM, 291–295
 - respiratory distress, 292
 - vertical transmission, 295
 - white matter damage, 292
 - Membrane stripping, 449
 - Membrane sweeping, 329
 - Mental health disorders,
 - psychiatric medications, 75–81
 - Metabolic health, 393
 - Metformin, 363, 502
 - Methergine, 476, 477
 - Methylenetetrahydrofolate
 - reductase (MTHFR) mutations, 167, 513
 - Microbial prevention, 424
 - Microcytic anemia, 84, 486
 - Minimal baseline variability, 418
 - Miscarriage, 452
 - Misoprostol, 316, 494
 - Mitochondria, 524
 - Moderate baseline variability, 385
 - Monochorionic-diamniotic twin gestations, 368
 - Monochorionic fetuses, 270
 - Monochorionic-monochorionic twin gestations, 368
 - Monochorionic pair, 520
 - Monochorionic twins, 310, 401
 - MRSA colonization, 350
 - Multifetal gestations, 392, 460, 487
 - ART techniques, 270
 - cervical insufficiency, 271
 - dichorionic-diamniotic twin gestations, 273–275
 - dichorionicity, 271
 - discordance, 273
 - fetal termination, 271
 - IUGR twins, 273
 - maternal age, 270
 - monochorionic fetuses, 270
 - preterm delivery, 271
 - preterm labor, 272
 - quadruplets, 270
 - spontaneous preterm birth, 269
 - tests, 272
 - twins, 273
 - twin-twin transfusion syndrome, 273, 274
 - uncomplicated pregnancies, 274
 - Multifetal pregnancies, 461
 - Multifetal reduction, 270
 - Multiple gestations, 414
- N**
- Naloxone, 525
 - Nausea and vomiting
 - acute pancreatitis, 214
 - causes, 210
 - diagnosis, 210
 - dietary counseling, 209
 - doxylamine, 215
 - early treatment, 209
 - enteral nutrition, 214
 - esophageal rupture, 211
 - family history, 211
 - gastric ulcer, 214
 - ginger pills, 212
 - hCG and estrogen, 211
 - helicobacter pylori, 214
 - human chorionic gonadotropin levels, 211
 - management, 209
 - medical management, 214
 - methylprednisolone, 213
 - motion sickness, 211

- multivitamins, conception, 212
 - ondansetron treatment, 213
 - placental mass, 211
 - psychosocial morbidity, 211
 - pyridoxine, 215
 - severe maternal effect, 211
 - splenic avulsion, 211
 - symptoms, 209
 - treatment, 210
 - Negative genital culture, 411
 - Negative predictive value, 321
 - Neonatal herpes infection, 54, 408
 - Neonatal hyperglycemia, 458
 - Neonatal injury, 226
 - Neonatal morbidity, 222
 - Neonatal mortality, 446
 - Neonatal phenotype, 444
 - Neonatal syndromes, 341
 - Neonatal withdrawal syndrome, 77, 80
 - Neonate, 525
 - Neural tube defects, 348, 362, 433, 434, 510, 523
 - anencephaly, 21
 - antiepileptic drugs, 21
 - diagnostics, 24, 26
 - diet, 22
 - epilepsy, pregnant patient, 25
 - ethnicity, 22
 - folic acid supplementation, 23, 24
 - genetic syndrome, 21, 26
 - high maternal core temperature, 22
 - intrauterine pregnancy, 22
 - latex allergy, 22, 26
 - maternal diabetes, 21, 22
 - preterm labor, 25
 - spina bifida, 21
 - Neuraxial analgesia, 9
 - Neuroprotection, 319
 - Nifedipine, 465
 - Nonprimary first episode, 405
 - Nonsteroidal anti-inflammatory drugs, 447–448
 - Nonstress test, 441–442
 - Nonviable pregnancy, 433
 - Normal XY fetus, 455
 - Nuchal fold measurements, 228–229
 - Nuchal translucency, 414, 460
 - Nulliparity and genetic predisposition, 321
- O**
- OASIS, 372, 416
 - repair, 360
 - Obesity
 - anovulation, 95
 - class III, 228, 324
 - definition, BMI, 95
 - in fertility, 95–96
 - fetal risks, 96
 - gestational diabetes, 96
 - oligoovulation, 95
 - operative morbidity, 96
 - ovulation induction, 96
 - oxytocin use, 96
 - preeclampsia, 96
 - in pregnancy, 374, 377
 - affects fertility, 323
 - behavioral interventions, 227
 - BMI, 225, 228
 - cefazolin, 229
 - childhood obesity, 226
 - class III obesity, 228
 - define, 322
 - fetal gastroschisis, 225
 - fetal macrosomia, 226
 - fetal risks, 324
 - gestational diabetes, 229
 - gestational weight gain, 227
 - impaired fetal growth, 226
 - low-molecular-weight heparin, 230
 - macrosomia, 227
 - maternal morbidity, 226
 - neonatal injury, 226

- Obesity (*cont.*)
- nuchal fold measurements, 228–229
 - obstructive sleep apnea, 229
 - overweight, 228
 - postpartum depression, 226
 - during pregnancy, 323
 - prevalence of, 321
 - primary cesarean section, 229
 - spontaneous preterm birth, 323
 - stillbirth, 226
 - subcutaneous tissue, 229–230
 - venous thromboembolism, 230
 - weight loss counsel, first trimester, 228
 - weight loss surgery, 227
 - prevalence, 95
- Objective pulmonary function, 332
- Obstetric anal sphincter injury, 428
- Obstetric lacerations, 258, 353
- Obstetric ultrasound examination, 371
- Obstructive sleep apnea, 229, 377
- Oligohydramnios, 419, 430, 465
- Ondansetron, 347, 369
- Operative vaginal deliveries, 388, 396, 431–432
- anal incontinence of solids, 219
 - category III fetal heart tracing, 326
 - cesarean sections, 218
 - rate of, 217
 - clinicians assessment, 517
 - episiotomies, 219
 - failed operative vaginal delivery, rate of, 221
 - and fetal macrosomia, 221
 - forceps and vacuum extraction, 220, 222
 - intracranial hemorrhage, 220
 - long-term effects, 220
 - maternal effort with pushing, 218
 - neonatal morbidity, 222
 - occiput posterior position, 221
 - potential indications for, 223, 506
 - provider feels chances, 222
 - rate of, 324
 - third or fourth degree laceration with forceps, 218
 - vacuum detachments, 222
 - vacuum extraction, 217, 219, 222
 - without anal sphincter laceration, 438
- Opioid consumption, 397
- Overt hypothyroidism, 192, 194–195
- diagnosis, 195
- Overweight, BMI, 95
- Oxytocin, 318, 365, 449
- P**
- Panic disorders, 445
- Parental iron, 344
- Parenteral analgesia, 9, 10
- Parvovirus B19, 340, 470–471, 509
- diagnosis, 205
 - erythroid precursors, 202
 - fetal infection, 390, 512
 - hand-to-mouth contact, 202
 - hydrops fetalis, 199
 - PCR analysis, amniotic fluid, 205
 - rash and arthritis, 201
 - respiratory secretions, 202
 - serology studies, 201
 - seropositivity prevalence, 202

- single-stranded DNA virus, 200
- symptoms, 201
- ultrasound evidence, 201
- ultrasound measurement, 205
- vertical transmission, 201
- Peak expiratory flow rate (PEFR), 436
- Penicillin, 529
 - allergy, 131
- Perinatal mortality, 317
- Perinatal vertical transmission, 348
- Perineal body, 474
- Perioperative antibiotic prophylaxis, 470
- Periventricular calcifications, 419
- PGE2 vaginal insert, 494
- Pitocin, 476, 477
- Placenta, 473, 474, 499
- Placenta accreta, 43, 493
- Platelet count, 386, 466, 494
- Platelet transfusion, 366
- Polycystic ovarian syndrome, 381
- Positive IgM antibodies, 341
- Postdural puncture headache, 453
- Postnatal death, 326
- Postpartum anticoagulation, 337
- Postpartum depression, 226
- Postpartum hemorrhage, 466, 468–469, 471, 497
 - amniotic fluid embolism, 41
 - causes, 39, 40
 - Haultain procedure, uterine inversion, 44, 45
 - hysterectomy, 45
 - indications, 43
 - labor and delivery schedule, 45
 - management, 39
 - post-spontaneous vaginal delivery, 40
 - primary vs. secondary, 39–40
 - retained placenta, 41
 - uterine artery embolization, 43
- Post-partum hysterectomy, 491
- Postpartum thyroiditis, 196–197, 375, 376
- Postterm pregnancies, 321, 329, 391, 420, 492
 - antenatal surveillance, 187
 - cesarean delivery, 188
 - due date estimation, 188, 190
 - incidence, 187
 - intrauterine pregnancy, 188, 189
 - low Apgar scores, 187
 - management, 189
 - meconium aspiration syndrome, 187
 - neonatal convulsions, 187
 - oligohydramnios, 189
 - primary cesarean delivery, 190
 - risk factors, 187–189, 321
 - stillbirth, 187
- Predict fetal well-being, 399
- Preeclampsia, 398, 446
- Pregestational diabetes mellitus, 398, 440
 - hypoglycemia, 29
 - insulin dosing, pregnancy, 28
 - insulin lispro, 28
 - neonatal complications, 30
 - perinatal mortality, pregnancies, 30
 - pregnancy outcomes, 27
 - type 1 diabetes
 - pancreatic beta cell destruction, 27, 32
 - patients with nephropathy, 30–31
 - type 2 diabetes, 27–29
- Pregnancy
 - allergen immunotherapy, 370
 - asthma, 369, 435, 456
 - corticosteroid, 504
 - depression during, 482
 - dyspnea of, 369

- Pregnancy (*cont.*)
- and hypertension, 406
 - hypertensive disorders, 458
 - hyperthyroidism of, 488
 - for intracranial hemorrhage, 383
 - laboratory values, 453
 - loss, 406
 - nausea and vomiting in, 342, 347, 367, 401, 412, 435–436, 470, 516, 529–530
 - overweight patient gain, 442
 - protein during, 524
 - thyroid changes in, 503
- Preimplantation genetic diagnosis, 516
- Premature infant, 478, 527
- Preterm birth, 389, 390, 419
- cervical length, 142–144
 - gestational ages, 141
 - iatrogenic, 141
 - morbidity, short- and long-term, 141
 - neonatal mortality, 141
 - preterm labor, 142
 - progesterone initiation, 144
 - severe preeclampsia, 143
 - singleton vaginal delivery, 142
 - smoking cessation, 141
 - spontaneous, 141
 - vaginal progesterone, 145
- Preterm labor, 323, 484, 500
- beta-adrenergic receptor agonists, 288
 - calcium channel blocker, 287
 - counsel, 284
 - gestational ages, 283–286
 - hospitalization, 284
 - magnesium sulfate, 288
 - multiple gestations, 288
 - nonsteroidal anti-inflammatory drugs, 287
 - premature infant, 283
 - steroid administration, 288
 - tocolysis, 287
 - tocolytic therapy, 285, 286
- Preterm PROM, 349, 354, 377, 443, 461, 478, 493
- Primary cesarean section, 229
- Procedure-related pregnancy loss rate, 395
- Progesterone, 346
- Progestin-only pills, 439
- Prolonged deceleration, 350
- Prolonged rupture of membranes, 408
- PROM, 423
- Prophylactic antibiotics, 336, 350
- in labor and delivery administration, 131
 - cefazolin, 131
 - E. coli* sepsis and resistance, 129
 - for endocarditis, 132
 - intraoperative dose, 131–132
 - lower serum levels, 130
 - manual placenta extraction, 133
 - patient screening, 132
 - resistant flora, 129
 - risk factors, 130
 - transverse cesarean section, 131
- Prophylactic anticoagulation, 343, 494
- Prophylactic cesarean section, 367
- Prophylaxis, 449
- Prostaglandin, 360
- Protein C deficiency, 169, 440
- Protein S deficiency, 169, 440
- Prothrombin, 440, 486
- Psychotropic medications, 474, 498
- amniotic fluid, 75
 - during pregnancy, 75
 - protein-binding properties, placental passage reduction, 76–77
- Pyridoxine, 332

R

- Randomized controlled trial, 372
- Red cell alloimmunization, 3
- Regional analgesia, 454
- Regional anesthesia, 10, 372, 433, 446
 - contraindications, 12, 15
 - epidural/spinal
 - hematoma, 14
 - side effects, 11
- Reverse uterine inversion, 497
- Rh alloimmunization, 521
- Rh negative, 354, 356, 389, 393, 401, 445, 447, 451, 521
 - women, 3–8
- Rh positive, 505
 - D antigen, 7, 505
- Rh prophylaxis, 464
- Roux-en-Y procedure, 324

S

- Schizophrenia, 78, 80, 81, 326, 467
- Selective fetal termination, 314–315
- Selective serotonin reuptake inhibitor (SSRI), 76, 81
- Sepsis, 525–526
- Serotonin reuptake inhibitor (SSRI), 520
- Serum screening, 415
- Sex discordance, 315
- Sexual activity, 364
- Shoulder dystocia, 17–19, 314, 513, 517, 525, 528
- Sickle cell anemia, 49, 486
- Sickle cell disease, 47, 477, 485, 487, 489
 - patient care, pregnancy, 50, 51
 - preterm labor, 49, 51
 - therapies, 50, 51
- Sickle cell pain crisis, 487
- Simplex virus infection, 427
- Sinusoidal pattern, 385
- SIRS, 479

- Small for gestational age (SGA)
 - birth, 353, 356
 - intrauterine infection, 152
 - maternal disorders, 152
 - multiple gestation, 152
 - tobacco use during pregnancy, 152
- Spina bifida, 21, 22, 24, 25, 247, 435, 437, 465, 477
- Spinal anesthesia, 512
 - duration of, 10, 15
 - postdural puncture
 - headache, 11
- Spinal hematoma, 362
- Spiramycin, 365
- SROM, 114, 423
- Sterile vaginal exam, 349
- Steroid administration, 500
- Stillbirth, 226, 400, 409, 446, 463, 471, 511, 516
 - abnormal karyotype, 90
 - amniocentesis, 90
 - coagulopathies, prolonged fetal retention, 93
 - delivery timing, 93
 - fetal autopsy, 91–92
 - fetal deaths, 89
 - fetal kick counting, 92
 - fetal tissue sampling, 90
 - gestational age, 91, 93, 94
 - induction method, 93
 - intrauterine growth restriction, 90
 - malarial infection, 91
 - management, 89
 - maternal evaluation, 92
 - monosomy, 90
 - obesity-related, 90
 - obstruction, umbilical cord
 - examination, 91, 94
 - parvovirus and syphilis, 91
 - patient management, 92
 - rates, 94
 - risk factors, 89, 92
 - trisomy, 90

Structural birth defects, 343
 Structural chromosomal
 abnormalities, 241
 Subcutaneous tissue, 229–230,
 376
 Supplemental sustained-release
 iron, 519
 Systemic corticosteroids, 475
 Systolic velocity, 400

T

Tachysystole, 127, 336, 350, 376,
 484
 Teratogen, 457
 Terbutaline, 395
 Thalassemias, 483
 Therapeutic anticoagulation, 316
 Thiamine, 353
 Three-dimensional
 ultrasonography, 427
 Thrombocytopenia, 316, 317, 325,
 386, 421, 422, 466
 anti-platelet antibody testing,
 265
 cesarean delivery, 265, 266
 chronic immune
 thrombocytopenia, 264
 ecchymosis, 261
 fetal intracranial hemorrhage,
 266
 fetal-neonatal alloimmune
 thrombocytopenia, 263,
 265
 gestational
 thrombocytopenia, 262,
 263
 hemolytic (Rh) disease, 264
 immune thrombocytopenia
 purpura (ITP), 263
 intracranial hemorrhage, 266
 intravascular coagulation
 dissemination, 264
 platelet count, 262, 264, 267
 platelet count
 antepartum, 265

 platelet counts, 262
 preeclampsia, 263
 pregnancies, 261, 267
 splenectomy, 266
 Thromboembolism, 464, 483
 breastfeeding, anticoagulants,
 140
 delivery preparation, 139
 factor V Leiden, 140
 heparin dosing, 136, 138
 monitoring labs, 139
 patient counselling, 137
 pelvic arteries compression,
 136
 risk, 135
 thrombophilia, women, 136
 treatment, 135
 warfarin, 137
 Thrombophilias, 332, 427, 440,
 472, 473, 486, 489, 513
 Thrombosis, 383, 424, 483
 Thyroid disease
 hormone synthesis, 192
 human chorionic
 gonadotropin, 191
 impaired neuropsychologic
 development, 193
 laboratory evaluation, 194
 maternal thyroid size, 191
 thioamides, 195
 ultrasound, 196
 umbilical cord blood
 sampling, 193
 Thyroid hormone, 462
 Thyroid laboratory evaluation,
 327
 Thyroid-stimulating hormone
 (TSH), 326, 396, 401,
 499, 504
 abruption, 193
 heart failure, 196
 overt hypothyroidism, 192
 preeclampsia, 193
 preterm birth, 193
 pulmonary hypertension, 196
 Thyroid storm, 195, 196, 411, 438

- Tocolysis, 320, 353
 Tocolytics, 320, 460, 464
 TORCH infection
 CMV (*see* Cytomegalovirus (CMV))
 parvovirusB19 (*see* Parvovirus B19)
 toxoplasmosis (*see* Toxoplasmosis)
 Varicellazoster (*see* Varicella zoster)
 Toxoplasmosis, 338, 413
 causes, 203
 congenital, 199
 congenital transmission, 203
 infected meat consumption, 199
 intracellular parasite, 203
 prevention, 206
 spiramycin, 206
 Toxoplasmosis infection, 365
 Transabdominal cerclage, 426
 Transcervical amnioinfusion, 460
 intrapartum fetal heart rate, 106
 Transient sinusoidal fetal heart rate, 458
 Transplacental exposure, 468
 Trial of labor after cesarean section (TOLAC), 339, 371, 412, 422, 480, 486–487
 African American ethnicity, 116
 cervical ripening, 120
 macrosomic fetus, 120
 maternal morbidity, 115
 mode of delivery, 115
 neonatal and maternal morbidity, 116
 patient counselling, 117
 short pregnancy interval, 116
 uterine rupture, 115
 with uterine rupture, 402–403
 Trisomy 13, 425
 Twins with isolated growth discordance, 345
 Twin-twin transfusion syndrome, 273, 274, 454
- U**
 Ultrasonography, 349
 Ultrasound, 248–250, 334, 339, 352, 381, 399, 409, 423, 424, 468, 490–491
 echogenic bowel, 375
 echogenic intracardiac focus, 375
 fetal weight by, 427
 Level I, 346
 Level II, 346
 macrosomia, 359
 middle cerebral artery Doppler assessment, 379
 in pregnancy
 abdominal circumference, 307
 amniotic fluid index (AFI), 309
 biparietal diameter, 307
 biparietal diameter, femur length, 309
 chromosomal abnormality, 309
 Doppler, 308
 femoral diaphysis, 307
 fetal anemia, 309
 fetal weight, 307
 gestational age, 306, 308
 IUGR, 310
 microbial prevention, 308
 monochorionic twins, 310
 nonviable pregnancy, 306
 obstetric ultrasound examination, 306
 prenatal diagnosis, 307
 settings, 305
 3D ultrasound, 308
 uterus and cervix, 306

- Umbilical artery, 411
- Umbilical artery Doppler velocimetry, 329
- Umbilical cord examination, stillbirth, 91, 94
- Urine pregnancy test, 484
- Uterine, 449
 - artery embolization, 43
 - bleeding, 490
 - contractions, 102, 415, 519
 - incision, 413
 - inversion, 497
 - rupture, 318, 381, 480, 486
- Uterine atony, 42
- Uterotonics, 42, 476, 490
- Uterus, 371

- V**
- Vacuum extraction, 388, 432
 - operative delivery, 325
- Vaginal birth after cesarean delivery (VBAC)
 - dose-response effect, 118
 - lower rates of hemorrhage, 116, 119
 - lower rates of infection, 116, 119
 - lower uterine incision, 119
 - shorter recovery
 - period, 116, 119
 - uterine rupture, 117–119
- Vaginal delivery, 344, 370, 521
 - bleeding, 473
 - obstetric lacerations
 - absorbable synthetic suture, 257
 - anal canal, 253
 - cervical laceration, 257
 - cohort investigation, 258
 - delayed pushing, 255
 - endoanal ultrasonography, 256
 - epidural anesthesia, 254
 - episiotomy, 254, 255
 - external anal sphincter, 253, 257
 - fourth-degree lacerations, 254, 255, 259
 - hemostatic first-degree laceration, 256
 - hemostatic laceration, 255
 - ischial tuberosity, 254
 - mediolateral episiotomy, 254, 255
 - midline episiotomy
 - combined with forceps, 254
 - OASIS define, 256
 - OASIS repair, 258
 - obstetric anal sphincter injury, 254
 - obstetric lacerations, 258
 - perineal massage, 255
 - shoulder dystocia, 255
 - wound infection, 258
- Vaginal progesterone, 346
- Variable decelerations, 317
- Varicella zoster, 479
 - infectivity period, 202
 - intrauterine pregnancy, 202
 - pneumonia, 202
 - vaccine administration, 206, 490
- Varicella-zoster-associated rash, 490
- Varicella zoster immune globulin (VZIG), 205
- Varicella-zoster immune globulin (VZIG), 379
- Venous thromboembolism, 165, 230, 337, 397, 424, 462
- Ventriculomegaly, 419
- Viable cells, 395
- Viral hepatitis, 329, 331, 333, 335
 - acute, 61
 - B cell lymphomas, 59
 - breastfeeding, 64
 - causes, 62
 - cesarean delivery, 64
 - chronic, 59, 61, 62
 - contraindications, 64
 - decreased appetite, 59

diagnosis, 63
fecal-oral transmission, 59
hepatocellular carcinoma, 59
mortality rate, hepatic failure,
61
natural infection, 62
nausea, 59
occupational exposure, 65
patient screening, 64
perinatal vertical
transmission, 64
right upper quadrant pain, 59
risk factors, 61

sexual transmission, 60
symptoms, 61, 63
types, 60, 62
vertical transmission, neonate,
59, 63
Vitamins, 353
and dextrose, 353

W

Warfarin, 503
Weight loss surgery, 227
Women, obesity, 374, 377